All Stories

  1. A Novel Pathogenic PSEN1 Variant in a Patient With Dystonia-Parkinsonism Without Dementia
  2. Genetics in Parkinson’s disease, state-of-the-art and future perspectives
  3. Speech, Gait, and Vestibular Function in Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome
  4. Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study
  5. Chorea‐Acanthocytosis Presenting with Parkinsonism‐Dystonia without Chorea
  6. Don’t forget Allgrove syndrome in adult patients as a bulbar-ALS mimicker
  7. The unexpected finding of CNS autoantibodies in GBA1 mutation carriers with atypical parkinsonism
  8. A form of inherited hyperferritinemia associated with bi-allelic pathogenic variants of STAB1
  9. SCARB1 downregulation in adrenal insufficiency with Allgrove syndrome
  10. Kufor Rakeb syndrome without gaze palsy and pyramidal signs due to novel ATP13A2 mutations
  11. Neuronopathic Gaucher disease models reveal defects in cell growth promoted by Hippo pathway activation
  12. Reply to: “Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort”
  13. Genetic Evidence for Endolysosomal Dysfunction in Parkinson’s Disease: A Critical Overview
  14. Whole-Exome Sequencing Study of Fibroblasts Derived From Patients With Cerebellar Ataxia Referred to Investigate CoQ10 Deficiency
  15. Deconstructing speech alterations in episodic ataxia type 2: Perceptual-acoustic analysis in a case due to CACNA1A gene mutation
  16. Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?
  17. Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
  18. iPSC-Derived Striatal Medium Spiny Neurons from Patients with Multiple System Atrophy Show Hypoexcitability and Elevated α-Synuclein Release
  19. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms
  20. Tremulous spastic ataxia in a patient with a homozygous truncating SYNE1 variant
  21. Two cases of Huntington’s disease unmasked by the COVID-19 pandemic
  22. A sensitive method for determining UDP-glucose: ceramide glucosyltransferase (UGCG) activity in biological samples using deuterated glucosylceramide as acceptor substrate
  23. Anderson–Fabry Disease: A New Piece of the Lysosomal Puzzle in Parkinson Disease?
  24. BiallelicSTAB1pathogenic variants cause hereditary hyperferritinemia
  25. Nuclear Pore Complex Dysfunction in Dystonia Pathogenesis: Nucleoporins in the Spotlight
  26. Approaching the Gut and Nasal Microbiota in Parkinson’s Disease in the Era of the Seed Amplification Assays
  27. SCARB1 downregulation in adrenal insufficiency with Allgrove Syndrome
  28. Reply to: No Association between Rare TWNK Variants and Parkinson's Disease in European Cohorts
  29. Adult-onset KMT2B-related dystonia
  30. A Bayesian approach to Essential Tremor plus: A preliminary analysis of the TITAN cohort
  31. Juvenile-onset dystonia with spasticity in Leigh syndrome caused by a novel NDUFA10 variant
  32. Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease
  33. Trial of Cinpanemab in Early Parkinson’s Disease
  34. β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration
  35. Changes in non-motor symptoms in patients with Parkinson's disease following COVID-19 pandemic restrictions: A systematic review
  36. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease
  37. Case Report: Effect of Targeted Therapy With Carbamazepine in KCNQ2 Neonatal Epilepsy
  38. TWNK in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study
  39. The apparent paradox of phenotypic diversity and shared mechanisms across dystonia syndromes
  40. Axial improvement after casirivimab/imdevimab treatment for COVID-19 in Parkinson Disease
  41. Correction to: The Italian tremor Network (TITAN): rationale, design and preliminary findings
  42. Cognitive and Autonomic Dysfunction in Multiple System Atrophy Type P and C: A Comparative Study
  43. Genetic evaluation in phenotypically discordant monozygotic twins with Coats Disease
  44. The Italian tremor Network (TITAN): rationale, design and preliminary findings
  45. Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review
  46. Progressive myoclonus without epilepsy due to a NUS1 frameshift insertion: Dyssynergia cerebellaris myoclonica revisited
  47. Dysautonomia in Parkinson’s Disease: Impact of Glucocerebrosidase Gene Mutations on Cardiovascular Autonomic Control
  48. Transcriptomic characterization of tissues from patients and subsequent pathway analyses reveal biological pathways that are implicated in spastic ataxia
  49. Role of Lysosomal Gene Variants in Modulating GBA ‐Associated Parkinson's Disease Risk
  50. A Practical Approach to Early-Onset Parkinsonism
  51. Freezing of gait: overview on etiology, treatment, and future directions
  52. VPS13C-associated Parkinson's disease: Two novel cases and review of the literature
  53. Transcriptome deregulation of peripheral monocytes in GBA-related Parkinson’s disease
  54. Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories
  55. Parkinsonism and ataxia
  56. The activities of LRRK2 and GCase are positively correlated in clinical biospecimens and experimental models of Parkinson’s disease
  57. A 79-year-old man with unexplained recurrent syncope and severe orthostatic hypotension
  58. Sodium Levels Predict Disability at Discharge in Guillain-Barré Syndrome: A Retrospective Cohort Study
  59. Screening of LRP10 mutations in Parkinson's disease patients from Italy
  60. Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia
  61. HOPS-associated neurological disorders (HOPSANDs): linking endolysosomal dysfunction to the pathogenesis of dystonia
  62. Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis
  63. Targeting the Autonomic Nervous System for Risk Stratification, Outcome Prediction and Neuromodulation in Ischemic Stroke
  64. Clinical features and disease course of patients with acute ischaemic stroke just before the Italian index case: Was COVID-19 already there?
  65. A novel homozygous VPS11 variant may cause generalized dystonia
  66. Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review
  67. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  68. Expanding the genotypic and phenotypic spectrum of Beta‐propeller potein‐associated neurodegeneration
  69. A case report of late-onset cerebellar ataxia associated with a rare p.R342W TGM6 (SCA35) mutation
  70. A rapid and low-cost test for screening the most common Parkinson's disease-related GBA variants
  71. Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity
  72. The SPID-GBA study
  73. Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum
  74. Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives?
  75. Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies
  76. GBA ‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort
  77. Late-onset leukoencephalopathy in a patient with recessive EARS2 mutations
  78. Nucleo–cytoplasmic transport defects and protein aggregates in neurodegeneration
  79. Design and Operation of the Lombardy Parkinson's Disease Network
  80. Pharmacological Antagonism of Kainate Receptor Rescues Dysfunction and Loss of Dopamine Neurons in a Mouse Model of Human Parkin-induced Toxicity 
  81. The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer’s Disease and Parkinson’s Disease
  82. Systemic involvement in adult‐onset leukoencephalopathy with intracranial calcifications and cysts (Labrune syndrome) with a novel mutation of SNORD118 gene
  83. SLC25A46 mutations in patients with Parkinson's Disease and optic atrophy
  84. Microscopic Polyangiitis With Selective Involvement of Central and Peripheral Nervous System: A Case Report
  85. Dystonia‐ataxia syndrome with permanent torsional nystagmus caused by ECHS1 deficiency
  86. Childhood onset dystonia with cerebellar signs: expanding the spectrum of GNAL mutations
  87. Loss of the nucleoporin Aladin in central nervous system and fibroblasts of Allgrove Syndrome
  88. Validation of the Italian version of the PSP Quality of Life questionnaire
  89. Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives
  90. Validation of the Italian version of carers’ quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy
  91. Neurofascin (NFASC) gene mutation causes autosomal recessive ataxia with demyelinating neuropathy
  92. GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
  93. Parkinsonism in diseases predominantly presenting with dystonia
  94. Spinal direct current stimulation (tsDCS) in hereditary spastic paraplegias (HSP): A sham-controlled crossover study
  95. Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy
  96. Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy
  97. LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study
  98. Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?
  99. Syncope and autonomic failure in a middle-aged man
  100. The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson’s Disease
  101. Clinical Reasoning: A 75-year-old man with parkinsonism, mood depression, and weight loss
  102. In vitro models of multiple system atrophy from primary cells to induced pluripotent stem cells
  103. A de novo C19orf12 heterozygous mutation in a patient with MPAN
  104. Real life evaluation of safinamide effectiveness in Parkinson’s disease
  105. X-linked Parkinsonism with Intellectual Disability caused by novel mutations and somatic mosaicism in RAB39B gene
  106. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p
  107. Progressive Encephalomyelitis with Rigidity and Myoclonus Associated With Anti-GlyR Antibodies and Hodgkin’s Lymphoma: A Case Report
  108. Mutations in TMEM230 are rare in autosomal dominant Parkinson's disease
  109. Globus pallidus internus deep brain stimulation in PINK-1 related Parkinson's disease: A case report
  110. Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients
  111. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson’s Disease
  112. Mutational analysis of COQ2 in patients with MSA in Italy
  113. Autophagy in motor neuron disease: Key pathogenetic mechanisms and therapeutic targets
  114. Abnormal brain temperature in early-onset Parkinson's disease
  115. Cerebellar and Motor Cortical Transcranial Stimulation Decrease Levodopa-Induced Dyskinesias in Parkinson’s Disease
  116. Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation
  117. Designing geographical indication institutions when stakeholders’ incentives are not perfectly aligned
  118. Adaptive deep brain stimulation in patients with Parkinson’s disease: phase II clinical trial preliminary results
  119. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis
  120. Adaptive deep brain stimulation in a freely moving parkinsonian patient
  121. A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism
  122. Cerebellar tDCS: How to Do It
  123. Lower motor neuron disease with respiratory failure caused by a novel MAPT mutation
  124. Biochemical markers in early diagnosis and management of systemic amyloidoses
  125. Obesity and Headache/Migraine: The Importance of Weight Reduction through Lifestyle Modifications
  126. Mutation in theSYNJ1Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism
  127. Mutations in DNA2 Link Progressive Myopathy to Mitochondrial DNA Instability
  128. Congenital Myasthenic Syndrome Due to Choline Acetyltransferase Mutations in Infants
  129. The novel mitochondrial tRNAAsn gene mutation m.5709T>C produces ophthalmoparesis and respiratory impairment
  130. Two novel mutations in PEO1 (Twinkle) gene associated with chronic external ophthalmoplegia
  131. Unusual adult-onset Leigh syndrome presentation due to the mitochondrial m.9176T>C mutation
  132. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability
  133. Autosomal dominant restless legs syndrome maps to chromosome 20p13 (RLS-5) in a Dutch kindred
  134. GIGYF2 mutations are not a frequent cause of familial Parkinson's disease
  135. The Mitochondrial Disulfide Relay System Protein GFER Is Mutated in Autosomal-Recessive Myopathy with Cataract and Combined Respiratory-Chain Deficiency
  136. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome
  137. Pseudo-orthostatic and resting leg tremor in a large spanish family with homozygous truncating parkin mutation
  138. The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population
  139. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
  140. LRRK2 MUTATION ANALYSIS IN PARKINSON DISEASE FAMILIES WITH EVIDENCE OF LINKAGE TO PARK8
  141. SPG11: a consistent clinical phenotype in a family with homozygous Spatacsin truncating mutation
  142. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
  143. Parkin polymorphisms and environmental exposure: Decrease in age at onset of Parkinson's disease
  144. LRRK2 mutations and Parkinson's disease in Sardinia—A Mediterranean genetic isolate
  145. High prevalence ofLRRK2 mutations in familial and sporadic Parkinson's disease in Portugal
  146. Neuropathology of Parkinson's disease associated with theLRRK2 Ile1371Val mutation
  147. 1.283 Clinical and genetic study of a large Dutch family with autosomal dominant restless legs syndrome
  148. 2.119 Parkin polymorphisms and environmental exposure: Reduction of Parkinson's disease age of onset
  149. LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample
  150. The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence
  151. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan
  152. Striatal dopamine transporter binding in Parkinson's disease associated with theLRRK2 Gly2019Ser mutation
  153. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
  154. A case of CPT deficiency, homoplasmic mtDNA mutation and ragged red fibers at muscle biopsy
  155. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease
  156. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor
  157. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease
  158. POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions
  159. Remarkable infidelity of polymerase  A associated with mutations in POLG1 exonuclease domain
  160. Novel missense mutation and large deletion ofGNE gene in autosomal-recessive inclusion-body myopathy